Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393
What this trial is testing

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Spanish Breast Cancer Research Group 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03366844
What this trial is testing

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Who this might be right for
Breast Cancer
Stephen Shiao 66
Large-scale testing (Phase 3)Study completedNCT02767661
What this trial is testing

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 263
Early research (Phase 1)Active Not RecruitingNCT06533059
What this trial is testing

Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Who this might be right for
CancerBreast CancerEndometrial Cancer+2 more
Alterome Therapeutics, Inc. 110
Not applicableNot Yet RecruitingNCT07180914
What this trial is testing

A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer

Who this might be right for
Breast Cancer Females
Zhejiang Cancer Hospital 300
Not applicableLooking for participantsNCT06388122
What this trial is testing

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Who this might be right for
HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more
Mayo Clinic 100
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Not applicableStudy completedNCT05022342
What this trial is testing

Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 595
Testing effectiveness (Phase 2)Study completedNCT07162051
What this trial is testing

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Xijing Hospital 28
Testing effectiveness (Phase 2)Ended earlyNCT04256941
What this trial is testing

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
M.D. Anderson Cancer Center 4
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)Looking for participantsNCT07616453
What this trial is testing

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Testing effectiveness (Phase 2)Study completedNCT03809988
What this trial is testing

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Who this might be right for
Breast CancerAdvanced Breast CancerHormone Receptor Positive Tumor+1 more
MedSIR 198
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Large-scale testing (Phase 3)Not Yet RecruitingNCT07683754
What this trial is testing

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

Who this might be right for
Advanced Breast CancerMetastatic Breast CancerHER2 Positive+1 more
Daiichi Sankyo 200
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Looking for participantsNCT06970912
What this trial is testing

CtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more
Peking University People's Hospital 393
Testing effectiveness (Phase 2)Looking for participantsNCT07497386
What this trial is testing

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Who this might be right for
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07336771
What this trial is testing

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 60
Next Page